MedTrace Logo

Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens

NCT05518539 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2025-07-18

Study results available
· View outcomes & findings →

Summary

To evaluate visual outcomes and quality of vision following bilateral implantation of the Clareon PanOptix intraocular lens (IOL) targeted for emmetropia.

Conditions

  • Cataract

Interventions

DEVICE

The Clareon™ PanOptix™ Trifocal (toric and non-toric models)

Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)

Sponsors & Collaborators

  • Sengi

    collaborator INDUSTRY

  • Newsom Eye & Laser Center

    lead OTHER

Principal Investigators

  • Thomas H Newsom, MD · Newsom Eye & Laser Center

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-08
Primary Completion
2024-06-14
Completion
2024-06-14
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05518539 on ClinicalTrials.gov